An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)

NCT02477826 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2747

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Nivolumab
DRUG: Ipilimumab
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Gemcitabine
DRUG: Pemetrexed
DRUG: Paclitaxel

Sponsor

Bristol-Myers Squibb

Collaborators

[object Object]